May 28, 2021 -- Humanigen requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use its drug lenzilumab in hospitalized COVID-19 patients.
This application follows positive results from the LIVE-AIR phase III clinical trial that showed lenzilumab improved the likelihood of survival without ventilation in newly hospitalized COVID-19 patients.